TRIM5 and fatty liver disease: Mechanistic studies have shown that DDX 5 inhibits downstream signaling by recruiting the TSC1/2 complex to mTORC1 to ameliorate NASH progression, and that TRIM5 exacerbates hepatic steatosis and inflammation in NASH by binding to and mediating the ubiquitination and degradation of DDX 5, inhibits autophagy, promotes NLRP 3 inflammatory vesicle activation, and exacerbates NASH liver steatosis and inflammation (60).